Goal
Translational
Research in Medicine and Pharmaceutics
The Science of what’s Vital
products, technologies and medicines with a full translation cycle for their rollout on the Russian and international markets
To set up a system for developing original
to set up a system for developing original products, technologies and medicines with a full translation cycle for their rollout on the Russian and international markets
Translational research
9
5-8
1-4
TRLs
Attraction of international customers and partners
Training in molecular pharmacology and translational medicine
Full-cycle translational research
Molecular modelling, synthesis and screening of new molecules
Strategic forecasting and evaluation of the current markets
Attraction of international customers and partners
Training in molecular pharmacology and translational medicine
Full-cycle translational research
Molecular modelling, synthesis and screening of new molecules
Strategic forecasting and evaluation of the current markets
2030
2020
Deliverables and results
For compliance with GxP
International certification
JCI accreditation
+ 160
Principal investigators
Graduates with competencies in the development and conduct of clinical research of medicines annually
1500 per year
Technological platform for creating medicines to treat viral diseases, cancer and autoimmune diseases
Diagnostic test systems for selecting personalised treatment of autoimmune diseases
Gene therapy drugs for the treatment of cancer, hereditary and autoimmune diseases
Products:
Of income from IPA commercialisation
500 mln ₽
Of revenues from translational R&D
5.4 bln ₽
Drugs developed by the University
> 10
Russian and international patents for medicines
> 40
© Sechenov University, 2021
2-4 Bolshaya Pirogovskaya str.
Moscow, Russian Federation
Moscow, Russian Federation
Sechenov University is a participant of the programmatic strategic academic leadership «Priority-2030»
